Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

102.69
+1.631.61%
Post-market: 102.690.00000.00%19:30 EDT
Volume:458.31K
Turnover:46.77M
Market Cap:4.67B
PE:50.09
High:102.89
Open:101.70
Low:100.53
Close:101.06
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.81
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.58
PE(LYR):50.09

Loading ...

Haemonetics Q4 Revenue USD 346.4 Million VS. Ibes Estimate USD 336.9 Million

THOMSON REUTERS
·
May 07

Haemonetics Outlook FY Organic Growth 3-6%

THOMSON REUTERS
·
May 07

Haemonetics Q4 EPS USD -0.44

THOMSON REUTERS
·
May 07

Haemonetics Q4 FY26 swings to loss of ($0.44) per share; revenue rises 4.8% to $346.4 million

Reuters
·
May 07

Press Release: Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Dow Jones
·
May 07

Haemonetics CEO Simon joins Bank of America Healthcare Conference fireside chat

Reuters
·
May 05

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

GlobeNewswire
·
May 04

Haemonetics Announces Upcoming Departure of Longtime Board Director

TIPRANKS
·
May 02

Haemonetics director Charles Dockendorff to step down from board at annual meeting

Reuters
·
May 02

Earning Preview: Haemonetics this quarter’s revenue is expected to increase by 2.27%, and institutional views are bullish

Earnings Agent
·
May 01

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.
·
Apr 29

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Haemonetics study shows VASCADE MVP XL outperforms VASCADE MVP in large-bore venous closure

Reuters
·
Apr 24

GVS FY25 net profit drops to EUR 18.4 million; revenue slips to EUR 424.7 million

Reuters
·
Apr 24

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

GlobeNewswire
·
Apr 20

Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating

TIPRANKS
·
Apr 16

BTIG Reaffirms Their Buy Rating on Haemonetics (HAE)

TIPRANKS
·
Apr 13

Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors

TIPRANKS
·
Apr 08

Haemonetics price target lowered to $64 from $70 at Citi

TIPRANKS
·
Apr 07

Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters
·
Apr 06